Novavax's 15min chart triggers Bollinger Bands expanding upward and downward.
PorAinvest
jueves, 14 de agosto de 2025, 3:43 pm ET1 min de lectura
NVAX--
Licensing, royalties, and other revenue for the second quarter of 2025 amounted to $229 million, which includes a $175 million milestone earned related to the Nuvaxovid BLA approval [1]. The cost of sales for the quarter was $15 million, down from $46 million in the same period last year, and R&D expenses were $79 million, down from $107 million. The company reported an earnings per share of 62 cents, a decline from 99 cents a year ago, and net income of $107 million, down from $162 million in the same period in 2024.
Novavax raised its fiscal year 2025 sales guidance from $975 million-$1.025 billion to $1 billion-$1.05 billion, with Nuvaxovid product sales for 2025 expected to be $610 million [1]. The company continues to work with the U.S. Department of Health and Human Services (HHS) on potential funding for its pandemic influenza vaccine candidate.
The stock price of NVAX has been volatile, trading higher by 19.5% to $8.042 at last check on Wednesday [1]. Analysts have given a mostly positive outlook for the stock, with Barchart Opinions indicating a composite indicator of 40% buy signals [2].
The Novavax 15-minute chart has triggered Bollinger Bands Expanding Upward and Bollinger Bands Expanding Downward as of August 14, 2025, at 15:30 [3]. This indicates that the market trend is being driven by buying pressure, while the trend is also being influenced by selling activity.
References:
[1] https://www.inkl.com/news/novavax-ups-outlook-eyes-stronger-nuvaxovid-sales
[2] https://www.barchart.com/stocks/quotes/nvax/opinion
[3] https://stockinvest.us/stock/NVAX
The Novavax 15-minute chart has triggered Bollinger Bands Expanding Upward and Bollinger Bands Expanding Downward as of August 14, 2025, at 15:30. This indicates that the market trend is being driven by buying pressure, while the trend is also being influenced by selling activity.
Novavax Inc. (NASDAQ: NVAX) reported its second-quarter 2025 sales totaling $239.24 million, surpassing the consensus estimate of $156.29 million [1]. This marks a significant improvement over the $415 million reported in the same period last year. The company's transition of Nuvaxovid commercial leadership in the U.S. to Sanofi SA (NASDAQ: SNY) for the 2025-2026 COVID-19 vaccination season was also completed during this period.Licensing, royalties, and other revenue for the second quarter of 2025 amounted to $229 million, which includes a $175 million milestone earned related to the Nuvaxovid BLA approval [1]. The cost of sales for the quarter was $15 million, down from $46 million in the same period last year, and R&D expenses were $79 million, down from $107 million. The company reported an earnings per share of 62 cents, a decline from 99 cents a year ago, and net income of $107 million, down from $162 million in the same period in 2024.
Novavax raised its fiscal year 2025 sales guidance from $975 million-$1.025 billion to $1 billion-$1.05 billion, with Nuvaxovid product sales for 2025 expected to be $610 million [1]. The company continues to work with the U.S. Department of Health and Human Services (HHS) on potential funding for its pandemic influenza vaccine candidate.
The stock price of NVAX has been volatile, trading higher by 19.5% to $8.042 at last check on Wednesday [1]. Analysts have given a mostly positive outlook for the stock, with Barchart Opinions indicating a composite indicator of 40% buy signals [2].
The Novavax 15-minute chart has triggered Bollinger Bands Expanding Upward and Bollinger Bands Expanding Downward as of August 14, 2025, at 15:30 [3]. This indicates that the market trend is being driven by buying pressure, while the trend is also being influenced by selling activity.
References:
[1] https://www.inkl.com/news/novavax-ups-outlook-eyes-stronger-nuvaxovid-sales
[2] https://www.barchart.com/stocks/quotes/nvax/opinion
[3] https://stockinvest.us/stock/NVAX
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios